Review anchor
Glucocorticoid receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Glucocorticoid receptor
CHEMBL2034
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Glucocorticoid receptor as ChEMBL target CHEMBL2034, mapped to UniProt P04150. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2034
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P04150
Glucocorticoid receptor
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Glucocorticoid receptor matters
Glucocorticoid receptor is reviewed as Glucocorticoid receptor (UniProt P04150); Glucocorticoid receptor shows approved-linked disease relevance led by asthma. 5 more disease programs remain visible in the same review block.; 22 linked drugs keep this evidence frame grounded.; the current evidence base includes 97 approved drugs, 6369 compounds, and 1143 assays, with lead potency reaching pChEMBL 10.7.
Protein context
Glucocorticoid receptor
Glucocorticoid receptor Sequence length is 777 aa.
Review this target as Glucocorticoid receptor, mapped to UniProt P04150. Sequence length is 777 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P04150
Protein
Disease context
asthma
Glucocorticoid receptor shows approved-linked disease relevance led by asthma. 5 more disease programs remain visible in the same review block. 22 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include AZD-5423, BECLOMETHASONE DIPROPIONATE, BETAMETHASONE ACETATE.
Start review with asthma because it currently carries approved-linked support. Linked drugs include AZD-5423, BECLOMETHASONE DIPROPIONATE, BETAMETHASONE ACETATE, BUDESONIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
22 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 97 approved drugs, 6369 compounds, and 1143 assays for this target. The dominant activity type is IC50. CHEMBL4104286 is the current potency anchor at pChEMBL 10.7.
Use CHEMBL4104286 as the tractability anchor when discussing potency (pChEMBL 10.7).
Activity source · ChEMBL 36 via Core Engine
97 approved
pChEMBL 10.7
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Glucocorticoid receptor matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P04150, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why asthma is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
6369
Total Compounds
1143
Total Assays
97
Approved Drugs
IC50: 5184.0, KI: 2277.0, EC50: 1731.0, KD: 16.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4104286
|
10.7 | IC50 | — |
|
|
No preferred name
CHEMBL4061359
|
10.5 | IC50 | — |
|
|
No preferred name
CHEMBL3911831
|
10.5 | IC50 | — |
|
|
No preferred name
CHEMBL3895181
|
10.5 | IC50 | — |
|
|
No preferred name
CHEMBL4086388
|
10.5 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
FLUTICASONE FUROATE
CHEMBL1676
|
2007 |
|
|
CICLESONIDE
CHEMBL2040682
|
2006 |
|
|
MIFEPRISTONE
CHEMBL1276308
|
2000 |
|
|
BUDESONIDE
CHEMBL1370
|
1994 |
|
|
PODOFILOX
CHEMBL61
|
1990 |
|
|
FLUTICASONE PROPIONATE
CHEMBL1473
|
1990 |
|
|
MOMETASONE FUROATE
CHEMBL1161
|
1987 |
|
|
CLOBETASOL PROPIONATE
CHEMBL1159650
|
1985 |
|
|
ETHINYL ESTRADIOL
CHEMBL691
|
1982 |
|
|
FLUNISOLIDE
CHEMBL1512
|
1981 |
|
|
DESOXIMETASONE
CHEMBL1766
|
1977 |
|
|
DIFLORASONE DIACETATE
CHEMBL1200545
|
1977 |
|
|
PROGESTERONE
CHEMBL103
|
1976 |
|
|
HALCINONIDE
CHEMBL1200845
|
1974 |
|
|
NORETHINDRONE ACETATE
CHEMBL1201146
|
1973 |
|
|
METHYLTESTOSTERONE
CHEMBL1395
|
1973 |
|
|
FLUOROMETHOLONE
CHEMBL1200600
|
1972 |
|
|
MEGESTROL ACETATE
CHEMBL1201139
|
1971 |
|
|
FLUOCINONIDE
CHEMBL1501
|
1971 |
|
|
NORGESTREL
CHEMBL2107797
|
1968 |
|
|
BETAMETHASONE PHOSPHORIC ACID
CHEMBL1201207
|
1965 |
|
|
FLURANDRENOLIDE
CHEMBL1201012
|
1965 |
|
|
FLUOCINOLONE ACETONIDE
CHEMBL989
|
1963 |
|
|
NORETHINDRONE
CHEMBL1162
|
1962 |
|
|
BETAMETHASONE
CHEMBL632
|
1961 |
|
|
TRIAMCINOLONE ACETONIDE
CHEMBL1504
|
1960 |
|
|
SPIRONOLACTONE
CHEMBL1393
|
1960 |
|
|
MEDROXYPROGESTERONE ACETATE
CHEMBL717
|
1959 |
|
|
DEXAMETHASONE
CHEMBL384467
|
1958 |
|
|
METHYLPREDNISOLONE
CHEMBL650
|
1957 |
|
|
TRIAMCINOLONE
CHEMBL1451
|
1957 |
|
|
PREDNISONE
CHEMBL635
|
1955 |
|
|
PREDNISOLONE
CHEMBL131
|
1955 |
|
|
FLUDROCORTISONE ACETATE
CHEMBL1201010
|
1955 |
|
|
HYDROCORTISONE
CHEMBL389621
|
1952 |
|
|
CHLORMADINONE ACETATE
CHEMBL110691
|
— |
Source Header